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ABSTRACT 
Objective: The present work was to formulate oral herbal tablets of Emblica officinalis extract and also with pure gallic acid, further to determine 
the dosage frequency through pharmacokinetic profiles obtained for the same.  
Methods: The Emblica officinalis fruits were suitably extracted and the concentration of gallic acid in Emblica officinalis extract was estimated by 
HPTLC (High-Performance Thin Layer Chromatography) with a comparison to pure form. Tablets were prepared with extract and synthetic form 
through direct compression technique by varying the process and formulation parameters. The formulated tablets were administered to rabbit 
models and their pharmacokinetic profile was studied after withdrawing blood samples through HPLC (High-Performance Liquid Chromatography). 
Results: The concentration of gallic acid in Emblica officinalis was found to be 8.21%. The pre and post compression parameters evaluated for the 
formulated batches found to be within the pharmacopoeial limits. The in vivo pharmacokinetic studies conducted in rabbit models showed that 
there were no significant differences with p-value between the pharmacokinetic data obtained for pure and extract gallic acid tablets. The Cmax was 
found to be 4.59±0.95 µg/ml in the extract form which was little low when compared to the pure form of 6.38±1.08 µg/ml. The t1/2 in the extract 
form was 6.0±0.33 h, whereas it was 4.92±0.36 h in the pure form of gallic acid. 
Conclusion: The Emblica officinalis extract tablet showed average t1/2 of 6 h, so about every 6 h one tablet compared to 4 h of t1/2 for pure gallic acid 
tablet can be the dosing frequency for the rabbit.  
Keywords: Emblica officinalis, Gallic acid, Pharmacokinetics, dosing frequency. 




Herbal drugs have been in use by different civilizations in different 
parts of the world for centuries to fight a large number of diseases. 
Many of these are in common use even today. With the emerging 
interest in the world to adopt and study the traditional system and 
to exploit their potentials based on different healthcare systems, the 
evaluation of the rich heritage of the traditional medicine is essential 
[1]. To reveal the active compounds of herbal medicines, in addition 
to chemical and pharmacological studies, pharmacokinetic study of 
herbal medicines is an important and necessary approach to 
elucidate the status and changes of active components in herbal 
medicines in the body, to explain and predict a series of events 
related to their efficacy and toxicity and finally to provide a firm 
basis for design of reasonable doses of clinical applications and 
pharmacological experiments [2]. So far, for most herbal medicines 
some basic and principal pharmacokinetic parameters of the 
isolated compounds have been reported but they were not linked or 
compared to the corresponding data in the whole herb and or herbal 
extract [3]. A significant shortcoming of this approach is that 
interactions among different ingredients cannot be observed only 
individual components are investigated, further, more 
pharmacokinetic data are usually available on only one or two 
ingredients which in most cases are markers rather than the main 
active principles in the investigated herbal medicines. This may 
mislead the interpretation of mechanisms of action, dosage design, 
and therapeutic monitoring during clinical applications of herbal 
medicines [4]. 
With the emerging interest in the world to adopt and study the 
traditional system and to exploit their potentials based on different 
healthcare systems, the evaluation of the rich heritage of the 
traditional medicine is essential. In conventional medicines, most 
remedies consist of synthetic drug preparation. Since herbal 
formulations consist of natural plant material and not a synthesized 
chemical, herbal remedies are less likely to cause unpleasant side 
effects than conventional pharmaceutical drugs. Thus, herbal 
remedies are précised safer, gentler and lower costing than 
conventional drugs [5-7]. 
Emblica Officinalis is a botanical that has been used since ancient times 
in Hindu and Ayurvedic traditional medicine. The fruit of the plant has 
been traditionally used for medicinal purposes and contains the active 
constituent gallic acid. The active constituent is an antimutagenic, 
anticarcinogenic and anti-inflammatory agent [8, 9]. 
This paper reports a comparative pharmacokinetic study on the 
formulation of oral herbal tablets of Emblica officinalis in extract 
form which was compared with the pharmacokinetic profile of the 
pure gallic acid formulation, which may be a reference to increase 
the efficacy, safety and quality for further research. Knowledge of 
herbal pharmacokinetics can provide valuable information to aid 
Practitioners in prescribing herbs safely and effectively. It may also 
enable useful predictions for dosing frequency based upon their 
half-life.  
MATERIALS AND METHODS 
Materials 
Emblica officinalis fruit was purchased from Annai Agencies 
(voucher no: AA4621), Ooty, Nilgiri District, Tamilnadu and 
authenticated by a Botanist from Central Council for Research in 
Ayurveda and Siddha, Tirunelveli, Tamilnadu. Gallic acid was 
purchased from Preet Remedies (Baddi). All other chemicals were of 
analytical grade. 
Extraction of gallic acid 
The Emblica officinalis fruits obtained were washed cut into pieces 
and the seeds were removed. Then the fruit was dried in shade for 
about 15 d and powdered. The powdered Emblica officinalis (10 gm) 
was extracted for 24 h with 100 ml of methanol using a shaker at 25 
°C and filtrated through 0.45 mm membrane filter paper. The 
residue was then extracted twice with 100 ml methanol. The 
combined methanolic extracts were concentrated by using a water 
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bath maintained at 40 °C. The residue was freeze-dried and then 
stored in an amber colored air-tight container at 40 °C, before 
further use [8, 9].  
Quantification of the extract by HPTLC 
The extract of gallic acid was quantified using standard drugs at 
273λmax of (CAMAC Linomat, iv, Switzerland) after the 
development of pre coated plates of 4*10 cm size (silica gel 60F 254, 
6. Merck). 
Preparation of samples 
The extract (100 mg) was weighed and dissolved in methanol. The 
flask was shaken for 30 min and then filtered through Whatman 
filter paper and the final volume was made up to 10 ml with 
methanol.   
Preparation of standard solutions  
Weighed 100 mg of extract was dissolved in 10 ml of methanol. 
From this 1.0 ml was diluted to 20 ml with methanol to produce 0.5 
mg/ml. The standard drugs solution were also prepared at a 
concentration of 0.5 mg/ml with methanol in a similar manner and 
used for the analysis.   
Application of standard and sample solutions 
For the application of the solutions, pre-coated plates of 4 x 10 cm 
size (Silica gel 60 F 254, E. MERCK) were used. The standards and 
the sample solutions were applied on different tracks of the plate. A 
thin band of 6 mm width was applied using Linomat IV (automatic 
TLC applicator, CAMAG, Switzerland).  
Chromatogram development and densitometric scanning  
After the development of the chromatogram through twin-trough 
chamber, the plates were taken out, dried and observed under UV 
light. The suitable solvent system selected for the quantification of 
gallic acid was toluene: ethyl acetate: formic acid in the ratio of 7:5:1 
v/v for the development of chromatogram. The developed plates 
were scanned using densitometer at 273 nm wavelength. The 
quantification of the gallic acid was calculated concerning standard 
solution [10].  
Formulation and evaluation of tablets 
Tablets of both synthetic gallic acid (300 mg) and the extract 
(equivalent to 3.2,8.4 mg of Gallic acid) were compressed (rotary 
tablet compressor, ten stations, Rimek, Ahmedabad, India) using 121 
nm standard concave punches by direct compression technique with 
varying the process and formulation parameters. All the powder 
mass was passed through the BSS-80 mesh and geometrically mixed 
in a polyethylene bag for 10 min. Then lubricant (aerosil) was added 
and mixed for an additional 5 min and then compressed. Prior the 
compression, the powder mixture evaluated for angle of repose, bulk 
density, compressibility index and drug content. Table 1 gives the 
formula of different batches [11, 12]. 
Precompression parameters 
The powder mixtures were studied for an angle of repose, bulk and 
tapped density, compressibility index, and drug content. The angle of 
repose was determined by funnel method using the below formula 
where h and r were the height and radius of the powder cone.  
Angle of repose= tan-1(h/r) (1) 
 
Table 1: Formula for the formulation of Emblica officinalis extract and gallic acid tablets 
S. No. Ingredients Pure gallic acid tablets (mg) Emblica officinalis extract tablets (mg)  
1 Gallic acid 300 - 
2 Emblica officinalis Extract  - 400 (Equivalent to 32.84 mg of Gallic Acid)  
3 Starch 1500 150 50 
4 MCC 26 26 
5 Croscarmellose 20 20 
6 Aerosil 4 4 
 
The bulk and tapped density were determined by taking the known 
quantity of slightly shaken powder mixture. These samples were, 
introduced to 50 ml measuring cylinder to record the bulk density. 
This is then allowed to fall under its weight onto a hard surface from 
the height of 2.5 cm at 2 sec interval. The tapping continued until no 
further change in volume was observed. The density was calculated 
based on the weight of powder to the volume occupied by it. The 
compressibility index was determined by analyzing the quantity of 
quinine extracted into phosphate buffer pH3 spectroscopically at 
λmax of 225 nm and expressed regarding percentage.  
	
 % = 100 −  ÷  (2) 
Where TD and BD represent tapped and bulk density respectively. 
Post-compression parameters  
Post compression parameters like weight variation (n=20), drug 
content (n=10), friability (n=tablet to whole weight of 6.2g), 
disintegration time (n=6) and hardness was determined. The test for 
post compression parameters except hardness performed as per IP 
2007. The drug content estimated for individual tablets. The 
hardness and friability were calculated using Monsanto hardness 
tester (Cadmach, Ahmedabad, India) and friability testing apparatus 
(Indian equipment, Mumbai, India). Then represents the number of 
tablets used for the test [13-15]. 
In-vitro drug release 
The dissolution medium consisted of 900 ml of phosphate buffer pH 
7.2, and the study was carried out for 90 min for the developed 
formulation maintained at 37 °C±0.5 °C. The drug release at different 
time intervals was measured by HPLC (Shimadzu) at 225 λ max. It 
made clear that none of the ingredients used in the matrix 
formulations interfered with the assay. The release studies conducted 
in triplicate and the mean values plotted versus time [16-18].  
Pharmacokinetic studies 
Animals  
Experiments were carried out on New-Zealand white rabbits of 
either sex 1.5±0.2 kg (mean±SD). The animals had overnight fasted 
before treatment but had free access to tap water. None subject was 
receiving any other drug at least two weeks before commencement 
of the study and no other drug permitted throughout the duration of 
the study. They randomly assigned into six groups (3 animals per 
group). Two groups received Gallic acid tablets, and two groups 
received Emblica officinalis extract tablets and one group as control. 
All experiments adhered to the institutional animal's ethics 
committee (JSSCP/IAEC/Projects/01/2008-09). 
Administration and Collection of blood samples 
The dose for the study taken was 35 mg and 70 mg of gallic acid 
from gallic acid tablets and extract tablets respectively calculated 
according to body weight and body surface area of rabbit with the 
help of conversion factor with the absolute human dose. The rabbits 
received the dose orally through an intragastric tube as 0.3% w/v 
CMC suspension. Blood samples (1 ml) were collected in heparinized 
tubes from the marginal ear vein at 0, 0.5, 1, 2, 4, 6, 8, 12, 24 h after 
the drug administration. The samples centrifuged at 3500 rpm for 
10 min to separate the plasma and they were transferred into 
airtight containers and stored at-20±0.2 °C until analyzed [20]. 
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Preparation of plasma samples 
The gallic acid extracted from plasma samples (1 ml) obtained from 
study subjects by the addition of 200 µl of perchloric acid to 
precipitate plasma proteins. The resulting solution was vortexed for 
5 min and centrifuged at 4000 rpm for 10 min. The supernatant 
layer was separated and analyzed by using Shimadzu gradient HPLC 
system [10]. 
Determination of gallic acid in plasma 
The gallic acid extracted from plasma samples and the supernatant 
layer was separated and analyzed by using Shimadzu gradient HPLC 
system with LC-20 AD 230V Solvent delivery system (Pump), 
Manual Injector 25 µl (Rheodyne), SPD-M20A 230V Photo diode 
array detector and LC solutions data station. Separation achieved at 
room temperature on a Phenomenex Gemini C18 (250x4.6 mm i.d., 
5µ) column. The mobile phase was a mixture of water and 
acetonitrile 97.5:2.5 v/v. The flow rate was 1.0 ml/min. The 
detection was done at 254 nm using SPD 20AD Diode Array 
Detector. 
Statistics 
All data expressed as mean value±standard deviation (SD). Statistical 
analysis was performed using ANOVA test (Tukey's test). Mean 
differences considered as statistically significant at a level of p<0.05.  
RESULTS AND DISCUSSION 
The extract of gallic acid from Emblica officinalis fruit done with 
methanol at 25 ⁰C for 24h then filtered. The residue was then 
extracted twice with 100 ml methanol then the methanolic extracts 
were combined and concentrated at 40 ⁰C, then freeze dried. The 
obtained extract was quantified for gallic acid by HPTLC with a 
comparison to the peak area obtained for 0.5 mg/ml methanolic 
solution of pure Gallic acid. The application volume of extract and 
the synthetic solution was 5 µl respectively.  
The pre-coated plates developed using mobile phase consisting of 
toluene: ethyl acetate: formic acid in the ratio of 7:5:1 v/v was scanned 
by densitometer at the wavelength of 273 nm. The result is shown in 
table 2, with the obtained peak area at Rf value of 0.73±0.2 it estimated 
that 8.21% of the gallic acid is present in the Emblica officinalis extract. 
 
Table 2: Quantification of gallic acid in the herbal extract by HPTLC 
S. No. Sample Rf Peak area Gallic acid (%w/w) 
1 Extract 0.73 1975.3  
8.21 2 Gallic acid 0.17 1741.5 
Rf= Retention factor 
 
The pure drug and the extract powder mixed with excipients in the 
geometrical pattern for 10 min and to confirm the uniform 
distribution of the drug the degree of mixing was carried. The drug 
content was 98.57 and 92.26% in case of pure drug and extract 
respectively. The further mixing led to demixing in the case of the 
pure drug, and no significant change was seen in the extract. 
The angle of repose gives a qualitative assessment of internal and 
cohesive-frictional forces. All the batches had an angle of repose less 
than 31 ° indicating good flow potential. The size and shape of the 
particles reflect the density of the material. The density is directly 
proportional to the number of spherical particles present whereas 
inversely to the size of the particles. As the value of compressibility is 
less than 15% in all the cases, the granules produced the adequate 
flow and stable packing. Table 3 shows the results of precompression 
parameters. 
Tablets of synthetic and extract were compressed by direct 
compression technique and the table 4 displaces their post 
compression parameters. The hardness of all the formulations was 
between 5.92 to 5.45±0.78 kg. The other parameters such as 
average weight, friability disintegration was found to be within 
limits. The drug content also showed more than 90% in both pure 
and extract tablets. MCC was used as binder cum diluent in the 
formulation as is widely used and croscarmellose used as the 
super disintegrant. The aerosil was used at the concentration of 
2% as it can nullify the use of additional lubricant as it can serve 
both as glidant and lubricant in a case of direct compression. 
Various trials have been done, and only the optimized batch 
formula is given in table No 1. With the satisfactory post 
compression parameters, the in vitro release studies were carried 
out in 900 ml of Phosphate buffer pH 7.2. The in vitro dissolution 
study was carried out for 90 min and the drug release at different 
time intervals was measured by HPLC at 225 nm. The in vitro 
release graph is shown in fig. 1 [16-18]. It was observed at the end 
of 90 min the release was about 99% in pure gallic acid tablets and 
88 % in extract tablets. 
A single dose study, for two concentrations (drug equivalent to 35 
mg and 70 mg) of Emblica officinalis extract and pure gallic acid, 
were carried out in five groups, containing three rabbits in each 
group, for each concentration of the formulations. The plasma 
samples were analyzed by reverse phase HPLC (Shimadzu UFLC 
LC20AD) with chromatographic conditions as water and acetonitrile 
in the ratio of 97.5:2.5 % v/v as mobile phase and phenomena. 
 
Table 3: Precompression evaluations for Emblica officinalis Extract and pure gallic acid blend 
S. No. Parameters Pure gallic acid blend Emblica officinalis extract blend 
1 Angle of repose (⁰ degree) 26.45±1.56 30.74±1.98 
2 Bulk density(g/cm3) 0.48±0.05 0.52±0.07 
3 Tapped density (g/cm3) 0.59±0.07 0.62±0.08 
4 Compressibility (%) 13.49±1.45 14.58±1.94 
5 Drug content (%) 98.57±1.78 94.26±1.53 
Values represent mean±SD, n=3.  
 
Table 4: Post compression evaluations for tablets 
S. No. Parameters Emblica officinalis extract tablets  Pure gallic acid blend tablets 
1 Average weight (mg) 499.25±2.96 497.12±2.56 
2 Hardness (Kg/cm2) 5.92±0.25 5.45±0.78 
3 Friability (%) 0.362±0.035 0.826±0.07 
4 Disintegration (minutes) 10.33±0.82 3.45±0.69 
5 Drug content (%) 90.45±1.39 97.72±1.83 
Values represent mean±SD, n=3. 
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Fig. 1: In vitro dissolution plots of Emblica officinalis extract and Gallic acid tablets, Results are given in mean of triplicate 
 
Table 5: Pharmacokinetic parameters of Emblica officinalis extract and pure gallic acid tablets  
S. No. Parameters Average of two doses 
Emblica officinalis extract  Pure gallic acid 
1 Cmax(µg/ml) 4.59±0.95 6.38±1.08 
2 Tmax (h) 1.5±0.53 1.75±0.78 
3 Keli (h-1) 0.116±0.38 0.140±0.03 
4 t ½(h) 6.0±0.33 4.92±0.36 
5 AUC(0-24) (µg. h/ml) 29.65±1.01 79.80±1.75 
6 AUC(0-∞) (µg. h/ml) 32.60±1.02 82.38±1.40 
7 Lag Time(t0) No No 
Values represent mean±SD, n=3, Cmax–Peak plasma concentration, tmax–Time to attain Cmax, keli–Elimination rate constant, t1/2–Half-life AUC–Area Under 
Curve, (t0)-Lag time 
 
Gemini phase C18 (250x4.6 mm, i.d. 5μ) as a stationary phase. The 
flow rate of mobile phase set at 1 ml/min, and the samples detected 
by LC solutions as the data station at 225 nm. The quantification of 
the chromatogram was performed using peak area ratios (response 
factor) of the drug to the internal standard. Table 5 provides the 
various PK parameters estimated by PK1 and PK2 software. The 
values present in the table represent the average values of two 
doses. From the results, it observed that all the Pharmacokinetic 
parameters determined showed a slight increase with the pure gallic 
acid tablets, but half-life was found to be comparatively high in 
extract tablets. The pharmacokinetic data obtained for the pure and 
the extract showed no significant difference which confirmed by 
application of one-way ANOVA followed by Tukey test [19-22]. 
DISCUSSION 
After the quantification of the Emblica officinalis extract, it was 
observed that 8.21% of the gallic acid is present in the Emblica 
officinalis extract. The preparation of tablets involves two basic 
techniques a) direct compression b) wet compression. The 
techniques have their advantages and disadvantages. The limitation 
of wet granulation is its cost. It is an expensive process because of 
labor, time, equipment, energy and space requirements, Loss of 
material during various stages of processing; Stability may be the 
major concern for moisture sensitive or thermo labile drugs, an 
inherent limitation of wet granulation is that any incompatibility 
between formulation components made us opts for direct 
compression. The leeway of the technique was minimized loss of 
mixing quantity for moisture sensitive material and improved 
disintegration since powder particles are not bonded together by a 
binder. The excipients in this study are common, used to formulate 
tablets. The MCC was used as a diluent, croscarmellose as the super 
disintegrant, aerosil as a glidant and lubricant. In the process of 
product development, some of the chemicals were added, omitted or 
varied in concentrations. The MCC is used as binder cum diluent in 
the formulation as is widely used in both the cases. But some 
researchers reported that MCC could sustain the release of the drug, 
to overcome this Croscarmellose used as the super disintegrant at 
the concentration of 5% w/w. At the concentration of 26 mg, the 
MCC provided the satisfactory post compression results in both pure 
and extract form. The aerosol was used at the concentration of 
2%w/w which can nullify the use of additional lubricant as it can 
serve both as glidant and lubricant. The other post compression 
parameters like Average weight, friability, disintegration, and drug 
content were found to be within limits. As the hardness increased 
the disintegration time prolonged, the increase in hardness may be 
due to inbuilt nature of the extract. With the optimized batch, the in 
vitro release was found to be satisfactory. The pharmacokinetic 
parameters for both the extract and the pure formulation were, 
evaluated directly after oral administration of them into the stomach 
of rabbits. The study was, carried to evaluate the difference in the PK 
parameters between the two formulations. The pharmacokinetic 
data obtained for the pure and the extract showed no significant 
difference. 
CONCLUSION 
The pharmacokinetic data obtained for the pure and the extract had 
no significant difference which was confirmed by application of one-
way ANOVA followed by Tukey test. The pharmacokinetic data 
obtained for pure and extract Gallic acid shows no significant 
difference in Cmax at Tmax. The Emblica officinalis extract tablets 
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showed an average t1/2 of 6 h and about every 6h one tablet 
(equivalent to a min of 35 mg of gallic acid) compared to 4 h of t1/2 
for pure Gallic acid tablet can be administered to the selected animal 
model as the dosing frequency. Further multiple dose studies are 
required to determine the exact dosage regimen. 
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